Targeting Cancer Treatment - Specific Factors Of A Patient's Tumor
6/03/2011
Cancer treatment is depending more and more today on specific factors of a patient's tumor, including gene mutations, or proteins that are commonly typical of certain cancer cells, rather than focusing on where in the body the cancer started. Before, treatment was based on finding where in the body the cancer originated, such as the breast or lung...
Women with early-stage hormone receptor-sensitive breast cancer* given zoledronic acid, a bone strengthening drug, in addition to standard hormone therapy for 3 years following surgery are at significantly (32%) less risk of their cancer returning, and the effect is long lasting, according to the long-term results of the landmark Austrian Breast and Colorectal Cancer Study Grou...
The targeted therapy cetuximab does not improve progression-free survival (PFS) or overall survival (OS) when added to standard chemotherapy as a first-line treatment for advanced colorectal cancer, according to the largest trial to date in advanced bowel cancer...
Canada's Two Largest Cancer Fundraisers Team Up To Conquer Cancer
6/03/2011
A landmark partnership announced today between Canada's two largest cancer charities, The Princess Margaret Hospital Foundation and the Canadian Cancer Society, will raise significant amounts of money towards conquering cancer through the national expansion of Road Hockey to Conquer Cancer...
Plexxikon Announces Combination Trials For Vemurafenib In Melanoma
6/03/2011
Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced new clinical trials in metastatic melanoma testing vemurafenib (PLX4032/RG7204) in combination with other state-of-the-art treatments, including an immunologic therapy and an investigational MEK inhibitor. Additionally, a new trial will test vemurafenib as a single agent in thyroid cancer patients who have the BRAF mutation...
Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, and Celgene Corporation (NASDAQ: CELG) today announced the initiation of the first part of a Phase 2/3 clinical study of ACE-011 (sotatercept) for the treatment of chemotherapy-induced anemia (CIA) in patients with metastatic non-small cell lung cancer (NSCLC)...
Bristol Myers, Roche Combine Know How; Combat Melanoma
6/03/2011
There are several ways to combat deadly melanoma. One way is to attack the cancer by bolstering the body's immune system to fight the disease. Another way is to block a genetic mutation known as BRAF, which may help the disease grow. This week it was announced that two giants, Bristol Meyers Squibb and Roche will combine forces to find a best practice solution...
Health Benefit Of Green Tea: Mechanism Discovered, New Approach To Autoimmune Disease
6/03/2011
One of the beneficial compounds found in green tea has a powerful ability to increase the number of "regulatory T cells" that play a key role in immune function and suppression of autoimmune disease, according to new research in the Linus Pauling Institute at Oregon State University...
Experimental Vaccine Made From Frozen Immune Cells Shows Promise For Prostate Cancer Patients
6/03/2011
Metastatic prostate cancer patients who received an investigational vaccine made from their own frozen immune cells lived 10 months longer than those not treated with it, according to data being presented by researchers from the Kimmel Cancer Center at Jefferson at the 2011 American Society of Clinical Oncology annual meeting in Chicago on Saturday, June 4...
New Therapy For Blood Cancers Develolped
6/03/2011
Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a Phase II clinical trial to test the safety and effectiveness of the new therapy...